Does This News Make Inovio Pharmaceuticals Stock a Buy?

It's been a rough 12 months for Inovio Pharmaceuticals (NASDAQ: INO). In the past year, shares of the company have declined by 35% while the S&P 500 has risen 30%. The main reason for this abysmal showing was Inovio's inability to keep up with some of its peers, such as Moderna, in the race to develop a coronavirus vaccine.

However, the biotech recently announced some encouraging regulatory news on that front. Let's look into the latest developments regarding Inovio's attempt to market its investigational coronavirus vaccine, INO-4800, and whether it is worth purchasing shares of the vaccine maker today.

Continue reading

Source Fool.com